CREDIT SUISSE AG/ - SUPERNUS PHARMACEUTICALS INC ownership

SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.

Quarter-by-quarter ownership
CREDIT SUISSE AG/ ownership history of SUPERNUS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,397,579
-13.3%
50,692
-5.4%
0.00%
-50.0%
Q2 2023$1,611,156
-3.7%
53,598
+16.0%
0.00%0.0%
Q1 2023$1,673,355
+2.4%
46,187
+0.8%
0.00%0.0%
Q4 2022$1,634,578
+6.6%
45,825
+1.1%
0.00%0.0%
Q3 2022$1,533,000
+17.7%
45,305
+0.6%
0.00%
+100.0%
Q2 2022$1,302,000
-27.0%
45,054
-18.4%
0.00%
-50.0%
Q1 2022$1,783,000
+16.3%
55,194
+5.0%
0.00%
+100.0%
Q4 2021$1,533,000
+10.8%
52,584
+1.2%
0.00%0.0%
Q3 2021$1,384,000
-21.9%
51,940
-9.7%
0.00%0.0%
Q2 2021$1,771,000
+26.7%
57,521
+7.8%
0.00%0.0%
Q1 2021$1,398,000
-63.6%
53,370
-65.0%
0.00%
-50.0%
Q4 2020$3,839,000
+7.1%
152,594
-11.3%
0.00%0.0%
Q3 2020$3,585,000
-19.3%
171,988
-8.0%
0.00%
-33.3%
Q2 2020$4,440,000
+47.1%
186,972
+11.4%
0.00%0.0%
Q1 2020$3,019,000
+103.4%
167,775
+168.3%
0.00%
+200.0%
Q4 2019$1,484,000
+7.1%
62,537
+24.1%
0.00%0.0%
Q3 2019$1,385,000
+35.1%
50,375
+62.6%
0.00%0.0%
Q2 2019$1,025,000
-35.8%
30,986
-32.0%
0.00%0.0%
Q1 2019$1,596,000
-23.7%
45,565
-27.6%
0.00%
-50.0%
Q4 2018$2,092,000
-40.9%
62,959
-10.4%
0.00%
-33.3%
Q3 2018$3,538,000
-27.0%
70,276
-13.2%
0.00%
-40.0%
Q2 2018$4,847,000
+26.3%
80,981
-3.4%
0.01%
+25.0%
Q1 2018$3,839,000
+56.8%
83,798
+36.4%
0.00%
+100.0%
Q4 2017$2,448,000
-15.8%
61,449
-15.5%
0.00%
-33.3%
Q3 2017$2,908,000
+18.6%
72,719
+27.9%
0.00%
+50.0%
Q2 2017$2,452,000
+0.9%
56,872
-26.8%
0.00%0.0%
Q1 2017$2,430,000
+22.4%
77,652
-1.3%
0.00%0.0%
Q4 2016$1,985,000
-12.2%
78,638
-14.0%
0.00%0.0%
Q3 2016$2,260,000
+23.2%
91,390
+1.4%
0.00%0.0%
Q2 2016$1,835,000
+379.1%
90,151
+259.4%
0.00%
Q1 2016$383,000
-42.0%
25,083
-48.9%
0.00%
-100.0%
Q4 2015$660,000
+37.8%
49,104
+43.9%
0.00%0.0%
Q3 2015$479,000
-74.9%
34,116
-69.6%
0.00%
-50.0%
Q2 2015$1,907,000
+64.1%
112,249
+16.8%
0.00%
+100.0%
Q1 2015$1,162,000
-13.1%
96,118
-40.4%
0.00%0.0%
Q4 2014$1,337,000
+84.2%
161,155
+92.7%
0.00%0.0%
Q3 2014$726,000
+250.7%
83,627
+341.7%
0.00%
Q2 2014$207,000
-72.7%
18,935
-77.7%
0.00%
-100.0%
Q1 2014$757,000
+11.2%
84,727
-6.2%
0.00%0.0%
Q4 2013$681,000
-6.5%
90,308
-9.1%
0.00%0.0%
Q3 2013$728,000
+395.2%
99,308
+278.2%
0.00%
Q1 2013$147,00026,2600.00%
Other shareholders
SUPERNUS PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
ASHFORD CAPITAL MANAGEMENT INC 698,676$41,816,0005.51%
Provident Investment Management, Inc. 543,194$32,510,0004.61%
NEUMEIER POMA INVESTMENT COUNSEL LLC 426,250$25,511,0002.37%
KOPP INVESTMENT ADVISORS LLC 41,879$2,506,0002.35%
AlphaOne Investment Services, LLC 126,279$7,558,0002.17%
Ranger Investment Management 468,933$28,066,0001.96%
Bruce & Co., Inc. 158,058$9,459,0001.88%
Penserra Capital Management LLC 244,371$29,030,0001.83%
SHAKER INVESTMENTS LLC/OH 49,642$2,971,0001.83%
Bridge City Capital, LLC 47,795$2,861,0001.81%
View complete list of SUPERNUS PHARMACEUTICALS INC shareholders